“Lynn is an experienced R&D leader with deep knowledge in the development of IV infusion pumps. Lynn will lead our talented R&D team and collaborate closely with Roger Susi, our founder and chief technology officer. I am confident his leadership and direct contributions to our current and future products will help drive our continued success. We are excited to add him to the executive team,” said McDonnell.
Neuhardt has extensive experience in the medical technology industry and specifically with IV infusion pumps. Prior to his appointment at IRADIMED, Neuhardt spent four years at ICU Medical Inc. as a director of Systems and Test Engineering. Prior to that, he spent more than 14 years at Hospira Inc., the former hospital products division of Abbott Laboratories, where he held various hardware and software design, development and testing engineering roles of increasing responsibility. Neuhardt is experienced in the development of IV infusion pumps and in all phases of new product development.
Neuhardt earned a bachelor of science degree in electrical engineering technology from the University of Minnesota.
Neuhardt's appointment follows the late February hiring of Steven Kachelmeyer as vice president of Regulatory Affairs and Quality Assurance.
Earlier this month, IRADIMED announced the issuance by the U.S. Patent and Trademark Office of a patent that expands on previous claims pertaining to the wireless remote control of IV infusion pumps.
The patent for invention number US 10,617,821 B2 relates to a system and method for remotely communicating with an infusion device, such as the company's MRI-compatible IV infusion pump.
“This patent protection further secures our MRI IV pump system technology. FDA also recently recognized the general usefulness of remotely controlling IV pumps and, in April 2020, issued recommendations for a COVID-19 enforcement policy that highlights the need and benefits of remotely controlling IV pumps. Such remote capability enhances isolation and safety for healthcare professionals and patients. Our invention supports that need and further solidifies our leadership position in innovating MRI compatible and remote-controlled medical devices,” said McDonnell. “This issuance marks our 13th U.S. patent and brings our total number of patents to 17.”